- Home
- KRON vs RANI Comparison
KRON vs RANI Comparison
Compare KRON & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRON
- RANI
- Stock Information
- Founded
- KRON 2017
- RANI 2012
- Country
- KRON United States
- RANI United States
- Employees
- KRON N/A
- RANI N/A
- Industry
- KRON Medicinal Chemicals and Botanical Products
- RANI Medicinal Chemicals and Botanical Products
- Sector
- KRON Health Care
- RANI Health Care
- Exchange
- KRON Nasdaq
- RANI Nasdaq
- Market Cap
- KRON 61.5M
- RANI 55.3M
- IPO Year
- KRON 2020
- RANI 2021
- Fundamental
- Price
- KRON $1.00
- RANI $1.66
- Analyst Decision
- KRON Buy
- RANI Strong Buy
- Analyst Count
- KRON 3
- RANI 6
- Target Price
- KRON $1.63
- RANI $11.33
- AVG Volume (30 Days)
- KRON 226.0K
- RANI 2.3M
- Earning Date
- KRON 03-20-2025
- RANI 03-19-2025
- Dividend Yield
- KRON N/A
- RANI N/A
- EPS Growth
- KRON N/A
- RANI N/A
- EPS
- KRON N/A
- RANI N/A
- Revenue
- KRON $9,864,000.00
- RANI N/A
- Revenue This Year
- KRON $62.21
- RANI N/A
- Revenue Next Year
- KRON N/A
- RANI N/A
- P/E Ratio
- KRON N/A
- RANI N/A
- Revenue Growth
- KRON 146.48
- RANI N/A
- 52 Week Low
- KRON $0.69
- RANI $1.24
- 52 Week High
- KRON $1.60
- RANI $8.75
- Technical
- Relative Strength Index (RSI)
- KRON 50.71
- RANI 54.80
- Support Level
- KRON $0.97
- RANI $1.59
- Resistance Level
- KRON $1.03
- RANI $1.90
- Average True Range (ATR)
- KRON 0.05
- RANI 0.15
- MACD
- KRON 0.00
- RANI 0.03
- Stochastic Oscillator
- KRON 65.52
- RANI 56.36
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.